Hologic (HOLX) said Wednesday it is working with the Centers for Disease Control and Prevention to develop reagents for laboratory tests aimed at detecting the H5N1 bird flu virus.
Financial terms were not provided.
The company said the agreement will fund the initial development of analyte-specific reagents, which are components for laboratory-developed tests. The reagents will be designed for use on Hologic's Panther Fusion system, it added.
While the reagents are not currently intended for commercial distribution, the company may consider commercialization if rapid H5N1 testing becomes necessary, Hologic said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments